Summary of findings 21. Fluoxetine compared to pramipexole.
| Fluoxetine compared to pramipexole | ||||||
| Patient or population: patients with depression Settings: in‐ and outpatients Intervention: fluoxetine Comparison: pramipexole | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Pramipexole | Fluoxetine | |||||
|
Failure to respond (reduction ≥ 50% on HDRS) |
657 per 1000 | 513 per 1000 (315 to 707) | OR 0.55 (0.24 to 1.26) | 105 (1 study) | ⊕⊕⊝⊝ low1 | |
|
Endpoint score (HDRS or MADRS) |
The mean endpoint score in the intervention groups was 0 standard deviations higher (0 to 0 higher) | 0 (0) | No data available on this outcome | |||
| Failure to complete ‐ total ‐ | 443 per 1000 | 87 per 1000 (23 to 250) | OR 0.12 (0.03 to 0.42) | 105 (1 study) | ⊕⊕⊝⊝ low1 | |
| Failure to complete ‐ inefficacy ‐ | 57 per 1000 | 29 per 1000 (3 to 215) | OR 0.49 (0.05 to 4.51) | 105 (1 study) | ⊕⊕⊝⊝ low1 | |
| Failure to complete ‐ side effects ‐ | 314 per 1000 | 27 per 1000 (5 to 186) | OR 0.06 (0.01 to 0.50) | 105 (1 study) | ⊕⊕⊝⊝ low1 | |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; OR: Odds ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested. Only one study included in the analysis.